

## Important update regarding coverage of Inflectra

In Canada, Pfizer Canada ULC and Celltrion Healthcare (CHC) have a commercial agreement, whereby, Inflectra (infliximab) is manufactured by CHC but promoted and distributed by Pfizer. Effective March 31, 2025 this agreement will come to an end and Pfizer will cease to promote Inflectra as of April 1, 2025.

To limit the impact this change will have on patients, a six-month transition period beginning April 1, 2025, will come into effect, whereby Pfizer will continue to distribute their remaining supply of Inflectra, and all patients enrolled in the PfizerFlex Patient Support Program (PSP) will continue to have access to this support program until September 30, 2025.

During the transition period, healthcare professionals will need to work with their patients to determine an alternate infliximab product they can transition to before September 30, 2025.

It is important to note that this discontinuation is not due to any safety, efficacy or quality issues, and while the product Inflectra will no longer be available as of September 30, 2025 – the Drug Identification Number (DIN) will still be in effect and launched by CHC under a new product name: Remdantry. This change will come into effect April 1, 2025. Patients who maintain or initiate treatment with Remdantry will be supported by Celltrion’s Connect Patient Support Program (“Celltrion Connect PSP”).

### Reimbursement during transition

During the transition period between April 1, 2025 and September 30, 2025, both Pfizer and CHC will have infliximab products available on the market under the same DIN. To differentiate these products, pharmacies are asked to adjudicate claims using the DIN/Product Identification Numbers (PIN) provided below in order to properly document patient care and the appropriate product that was dispensed:

Manufacturer	Drug Name	Molecule	DIN/PIN	ADBL Price
Pfizer	Inflectra	infliximab	66128531	\$525.0000 per vial
Celltrion	Remdantry	infliximab	02419475	\$493.0000 per vial

### Special Authorization

Patients who have a Special Authorization approval in effect for Pfizer labelled Inflectra should work with their health care provider to transition to an alternate infliximab biosimilar listed on the Alberta Drug Benefit List (ADBL) by September 30, 2025, if applicable. Health care providers do not need to submit a new Special Authorization request for a different infliximab biosimilar, but patients may require a new prescription, as appropriate.

*continued next page*

*continued from previous page*

### Government Sponsored Plans

Effective April 1, 2025, all new Special Authorization requests for Pfizer labelled Inflectra for treatment naïve patients will no longer be approved. Infliximab naïve patients will need to be assessed for coverage with other currently listed infliximab biosimilars and will require an appropriate prescription.

---

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

**780-498-8370** (Edmonton and area)

**403-294-4041** (Calgary and area)

**1-800-361-9632** (toll free)

**FAX 780-498-8406** (Edmonton and area)

**FAX 1-877-305-9911** (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct-bill drug claims.

Visit [ab.bluecross.ca/providers/pharmacy-home.php](https://ab.bluecross.ca/providers/pharmacy-home.php)

